



ANNUAL MEETING OF THE SWEDISH AML-GROUP - January 19, 2017 - Arlanda hotellby

09.30-10.00 Årsmöte Svenska AML-gruppen

10.00-10.15 Coffee

10.15- 11:30 SCIENTIFIC PROGRAM I (Chair Anna Eriksson)

10.15-10.45 Updated national APL guidelines - clinical implications (Sören Lehmann)

10.45-11:30 Immunologic activation during treatment with IL2/histamin (Fredrik Thorén and Anna Martner)

11.30-12.15 Lunch

12.15-14.00 SCIENTIFIC PROGRAM II (Chair Stig Lenhoff)

12.15-13.15 Treatment after allogeneic stem cell transplantation (prof. Jan Cornelissen)

13.15-13.45 Preliminary data from TRALG – RICT study (Mats Brune)

13.45-14.00 Updates from the national acute leukemia biobank and new regulations (Sören Lehmann)

14.00-14.30 Coffee

14.30-15.45 SCIENTIFIC PROGRAM III (Chair Stefan Deneberg)

14.30-15.15 Ongoing/ future trials

HOVON 132 AML (Martin Höglund)

Future HOVON-studies (Martin Höglund)

AML studies open for inclusion in Sweden (Stefan Deneberg)

Haplo-SCT vs URD in AML (Mats Brune/Per Ljungman)

Molecular MRD follow-up after allogeneic stem cell transplantation in MDS (Magnus Tobiasson)

15.15-15.45 Swedish AML registry report (Gunnar Juliusson)

Mötet sponsras av



SUNESIS

Pharmaceuticals, Inc.